HIV Antigens

HIV Full Name

Human Immunodeficiency Virus

HIV Introduction

Human immunodeficiency virus type 1 (Human immunodeficiency virus 1, HIV-1) is an enveloped, positive-sense RNA retrovirus whose structural organization underpins its capacity for immune evasion, cellular tropism, and persistent infection. The viral particle is built around a conical capsid composed of CA protein, enclosing two copies of genomic RNA associated with nucleocapsid (NC) and the viral enzymes reverse transcriptase, integrase, and protease. Surrounding this core is a host-derived lipid envelope studded with trimeric envelope glycoprotein (Env) spikes composed of gp120 and gp41. Env is the principal determinant of viral entry and antigenicity: gp120 mediates receptor binding, while gp41 executes membrane fusion. Structurally, Env exists as a metastable trimer that undergoes large conformational rearrangements upon receptor engagement. High glycan density across gp120 forms a "glycan shield," masking conserved epitopes and contributing to neutralization resistance. The sparse distribution and conformational flexibility of Env trimers further limit antibody accessibility. Together, the capsid architecture, enzymatic cargo, and heavily glycosylated Env define HIV's structural strategy—compact yet dynamic, shielded yet adaptable—providing the framework for its functional mechanisms and for intervention strategies targeting structural vulnerabilities.

Functionally, HIV entry is a multistep process initiated by gp120 binding to the CD4 receptor, followed by interaction with one of two principal chemokine coreceptors, CCR5 or CXCR4. Coreceptor engagement triggers gp41 refolding, insertion of its fusion peptide into the host membrane, and formation of a six-helix bundle that drives membrane fusion. Notably, studies suggest that a single functional Env trimer may suffice to mediate entry, highlighting the efficiency of the fusion machinery and the need for highly potent inhibitors. Entry can occur at the plasma membrane or through endocytic routes depending on cell type, reflecting pathway plasticity rather than a single universal mechanism. Following fusion, reverse transcription converts viral RNA into DNA, which is transported into the nucleus and integrated into the host genome, establishing lifelong persistence. Structural transitions in the capsid regulate uncoating kinetics and nuclear import, linking particle architecture directly to replication efficiency. Viral diversity—arising from error-prone reverse transcription and recombination—drives variation in Env structure, coreceptor usage, and fusion kinetics, complicating both immune recognition and drug susceptibility. Thus, HIV's functional cycle is inseparable from its structural plasticity: conformational change, receptor adaptation, and replication dynamics operate as an integrated system enabling chronic infection.

These structural and mechanistic insights have profoundly shaped vaccine and antiviral development. Entry inhibitors represent a validated therapeutic class, exemplified by the gp41-targeting fusion inhibitor Enfuvirtide, which blocks six-helix bundle formation and prevents membrane fusion. Small-molecule CCR5 antagonists and attachment inhibitors further demonstrate the feasibility of targeting discrete entry steps. Beyond synthetic compounds, lectin-like proteins such as Cyanovirin-N interfere with gp120 glycan interactions, illustrating alternative strategies that exploit structural features of Env. However, Env variability and glycan shielding pose formidable challenges for vaccine design. Broadly neutralizing antibodies (bnAbs) targeting conserved regions—such as the CD4-binding site, V3 glycan supersite, or membrane-proximal external region (MPER)—provide proof of principle that vulnerable epitopes exist despite structural masking. Vaccine strategies increasingly aim to stabilize native-like Env trimers to present these conserved conformations while minimizing exposure of non-neutralizing epitopes. Meanwhile, combination antiretroviral therapy integrates entry inhibitors with reverse transcriptase and integrase inhibitors to suppress replication and limit resistance. From a public health perspective, understanding clade-specific variation in coreceptor usage and Env structure informs geographically tailored therapeutic and vaccine strategies. Overall, the interplay between HIV's structural architecture, its finely tuned entry and replication mechanisms, and the host immune response defines both the challenge and the opportunity in combating infection. Continued integration of structural biology, mechanistic virology, and translational immunology remains essential for advancing next-generation vaccines and antiviral interventions.

Alternate Names for HIV

Group VI (ssRNA-RT); Retroviridae; Lentivirus HIV; Human Immunodeficiency Virus type 1, type 2, and Subtype O; HIVSav 1/2/0

• 1. Adetokunboh O., et al. Antiretroviral Treatment and Resistance Patterns in HIV-Infected Children. Current Infectious Disease Reports. 2015.
  2. Baesi K., et al. Antiretroviral drug resistance among antiretroviral-na?ve and treatment experienced patients infected with HIV in Iran. Journal of Medical Virology. 2014.
  3. Brust J.C.M., et al. Directly Observed Antiretroviral Therapy in Substance Abusers Receiving Methadone Maintenance Therapy Does Not Cause Increased Drug Resistance. AIDS Research and Human Retroviruses. 2011.